Navigation Links
AirXpanders Announces AeroForm Now Available in More than 100 Medical Institutions and Health Systems in the U.S.
Date:6/9/2017

PALO ALTO, Calif., June 9, 2017 /PRNewswire/ -- AirXpanders, Inc. (ASX: AXP) (AirXpanders or Company), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today updated the market on the progress of its commercial roll-out in the United States. AeroForm is now available in more than one hundred (100) medical institutions and health systems, located throughout the country.

AeroForm offers a needle-free alternative for women who choose reconstructive surgery following a mastectomy. AeroForm is activated by a handheld wireless controller that administers small amounts of carbon dioxide (CO2) up to three times a day, to gradually stretch the tissue to prepare for a breast implant. With the push of a button from the wireless controller, a preprogrammed amount of CO2 is delivered in seconds, allowing the patient to continue with her daily activities while preparing for reconstruction. AeroForm was granted de novo clearance by the U.S. Food and Drug Administration (FDA) on December 21, 2016.

"AeroForm provides a solution we have long been looking for in breast reconstruction. For decades, women opting for two-stage reconstruction have had to undergo a cumbersome, uncomfortable and often logistically difficult process to expand their tissue prior to reconstructive surgery," said Neil Tanna, MD, MBA, a Long Island, N.Y.-based plastic surgeon who recently added AeroForm into his practice. "After reading multiple clinical studies about AeroForm I knew it was an option that I wanted to offer to my patients having reconstruction. I believe this needle-free, patient-controlled device will improve my patients' experiences and empower them to take back control of their time and bodies after often long journeys through breast cancer."   

"We believe that AeroForm approval by medical institutions and health systems in cities across the U.S. speaks to the medical community's enthusiasm for this technology and its potential to positively redefine reconstruction in their practice and for their patients," said Scott Dodson, president and CEO of AirXpanders. "As the AirXpanders team continues a targeted market release, we look forward to working with additional providers to broaden patient access to this innovative product, which we believe stands to elevate the standard of care for reconstruction."

Company

Investor and Media Relations

Scott Dodson
President & CEO
Tel: +1 (650) 390-9008

Email: sdodson@airxpanders.com  

Wendy Ryan/Michelle Thaler
MSLGROUP
Tel: +1 (781) 684-0770
Email: airxpanders@publicisgroupe.com

About AirXpanders:

Founded in 2005, AirXpanders, Inc. (www.airxpanders.com) designs, manufactures and markets innovative medical devices to improve breast reconstruction. The company's AeroForm Tissue Expander System, is used in patients undergoing two-stage breast reconstruction following mastectomy.  Headquartered in Palo Alto, California, AirXpanders' vision is to be the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction.  AirXpanders is a publicly-listed company on the Australian Securities Exchange under the symbol "AXP." AeroForm was granted U.S. FDA de novo marketing authorization in 2016, first CE mark in Europe in 2012 and is currently licensed for sale in Australia. 

Foreign Ownership Restriction:

AirXpanders' CHESS Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of AirXpanders' CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements:

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as, our expectations with respect to our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; ability to become the global leader in reconstructive surgery products and to become the standard of care in two-stage breast reconstruction.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. AirXpanders does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. AirXpanders may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For more information, refer to the Company's website at www.airxpanders.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/airxpanders-announces-aeroform-now-available-in-more-than-100-medical-institutions-and-health-systems-in-the-us-300471605.html


'/>"/>
SOURCE AirXpanders
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. AirXpanders Completes Enrollment in XPAND US Pivotal Trial
2. AirXpanders XPAND Pivotal Trial Meets Primary Endpoint
3. AirXpanders Expands US Team to Bring Revolutionary Breast Reconstruction Technology to Market
4. AirXpanders Raises A$45 Million ($34 Million USD) in Private Placement
5. Pharmagen Announces First Quarter 2013 Results
6. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
7. Vasomedical Announces Financial Results for the First Quarter of 2013
8. TSI Announces 2013 Respiratory Protection Roadshow Training Dates and Locations
9. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
10. Active Life Announces $500K Follow On Series A Investment - Tech Coast Angels Re-up
11. Pentec Health Announces Limited Voluntary Recall of Certain Compounded Prescription Therapies for Renal Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2019)... , ... October 14, 2019 ... ... LP2 linearity and calibration verification kit, for Roche cobas® analyzers, Order No. ... Apolipoprotein B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, and prepared ...
(Date:10/15/2019)... ... October 14, 2019 , ... An October 4 article on ... correlation between tooth loss and heart disease. The researchers found that individuals between 40 ... of also having heart-related problems, compared to just seven percent for those who never ...
(Date:10/11/2019)... ... October 11, 2019 , ... ... 13, 2019, to recognize the dedication, compassion and quality patient outcomes achieved by ... providing a unique and vital link between patients, providers and payers to improve ...
Breaking Medicine Technology:
(Date:10/10/2019)... ... , ... AltMed Florida , one of the fastest growing Medical Marijuana ... opening of its second MÜV™ Medical Cannabis Dispensary on the First Coast – scheduled ... Beach. , Located at Beach Plaza Shopping Center at the corner of Beach Boulevard ...
(Date:10/8/2019)... ... 2019 , ... Safe Harvest soups in glass jars launch ... Roundy’s, Smiths and Dillons. , Safe Harvest reinvented classic soup recipes to make ... fresh taste is paramount for us,” says Bryan Boches, co-founder of Safe Catch. ...
(Date:10/8/2019)... , ... October 08, 2019 , ... Dr. Amir HagShenas ... in San Jose, CA experience relief from this common and treatable condition. Dr. HagShenas’ ... to save adults from living with uncomfortable symptoms, including tender and bleeding gums, and ...
(Date:10/8/2019)... ... October 08, 2019 , ... PotentiaMetrics, an Austin, TX based ... Chief Medical Officer. Dr. Henderson will be responsible for the development and management ... served as Chair of both the Informatics Governance and the Inpatient Clinical Informatics ...
(Date:10/8/2019)... ... ... Smile Brands Inc. has been named one of the happiest companies in the ... support organization with nearly 440 affiliated practices across 18 states, has a deeply rooted ... is the latest in a series of accolades the company has received ...
Breaking Medicine News(10 mins):